Annual report pursuant to Section 13 and 15(d)

Investments in unconsolidated entities - Additional Information (Detail)

 v2.3.0.11
Investments in unconsolidated entities - Additional Information (Detail) (USD $)
12 Months Ended
Jun. 30, 2010
Jun. 30, 2011
Chemo Centryx, Inc.
   
Investments in and Advances to Affiliates [Line Items]    
Net investment on a cost basis $ 14,300,000 $ 14,300,000
Ownership percentage on a cost basis   16.60%
Cost method investments, statement that fair value was not estimated The Company has not identified any events or changes in circumstances that may have had a significant adverse effect on the fair value of the investment.  
Nephromics, LLC
   
Investments in and Advances to Affiliates [Line Items]    
Percentage of Investment in equity interest   16.80%
Net investment under equity method 4,000,000 3,700,000
Hemerus Medical, LLC
   
Investments in and Advances to Affiliates [Line Items]    
Percentage of Investment in equity interest   8.30%
Net investment under equity method 1,200,000 773,000
ACTGen, Inc.
   
Investments in and Advances to Affiliates [Line Items]    
Net investment on a cost basis $ 1,100,000 $ 925,000
Ownership percentage on a cost basis   13.60%